Gene
CD274
CD274 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (270), Actionable biomarkers (7), Trial mentions (1,080), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CD274. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 3 with a planned future start and 4 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 542 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 67 of 8,738 | 0.77% | not measured | |
| 2025 | 61 of 8,875 | 0.69% | not measured | |
| 2024 | 76 of 8,597 | 0.88% | not measured | |
| 2023 | 80 of 8,275 | 0.97% | 638 of 11,460 | 5.57% |
| 2022 | 85 of 8,285 | 1.03% | 708 of 13,598 | 5.21% |
| 2021 | 120 of 8,692 | 1.38% | 666 of 15,045 | 4.43% |
| 2020 | 90 of 7,640 | 1.18% | 577 of 14,459 | 3.99% |
| 2019 | 99 of 7,300 | 1.36% | 444 of 12,159 | 3.65% |
| 2018 | 103 of 6,927 | 1.49% | 348 of 11,854 | 2.94% |
| 2017 | 114 of 6,558 | 1.74% | 267 of 11,595 | 2.30% |
Showing 10 of 37 years.
Assay-provider ledger (270)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BIO-RAD | Reagent supplier | Clinical validationAnalytical validation | 2 | September 01, 2026 +1 undated |
| NKGen Biotech | Diagnostic provider | Clinical validationAnalytical validation | 1 | September 01, 2026 |
| NKMAX | Diagnostic provider | Clinical validationAnalytical validation | 1 | September 01, 2026 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 10 | September 01, 2026 +1 undated |
| R & D Systems | Reagent supplier | Clinical validationAnalytical validation | 5 | September 01, 2026 +1 undated |
Showing 5 of 270 assay-provider companies.
Actionable biomarkers (7)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CD274 amplification | Pd1 Ab Inhibitors | response-associated | basal cell carcinoma | Cancer Genome Interpreter |
| CD274 overexpression | ATEZOLIZUMAB | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| CD274 overexpression | NIVOLUMAB | response-associated | renal carcinoma | Cancer Genome Interpreter |
| CD274 overexpression | ATEZOLIZUMAB | response-associated | renal carcinoma | Cancer Genome Interpreter |
| CD274 overexpression | ATEZOLIZUMAB | response-associated | No disease recorded | Cancer Genome Interpreter |
Showing 5 of 7 actionable-biomarker assertions.
Trial mentions (1,080)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07597369 | Trial biospecimen (AACT) |
| NCT03014284 | Trial biospecimen (AACT) |
| NCT06833632 | Trial biospecimen (AACT) |
| NCT05447702 | Trial eligibility (AACT) |
| NCT06265350 | Trial eligibility (AACT) |
Showing 5 of 1,080 trial mentions.
Target-disease associations (1,119)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adenosquamous Carcinoma | cancer or benign tumor | Literature (Europe PMC) |
| Adrenal Gland Myelolipoma | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 1,119 associations.
Vendor sourcing (3,422)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ADC Therapeutics SA | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | may supersede the general ones, such as stem cell transplant. * Prior allogeneic stem cell transplant and solid organ transplant * Autologous stem cell tran... | View trial NCT04970901 |
| ADC Therapeutics SA | Trial sponsor | Mentioned in trial textTrial free-text mention | PDL1 | View trial NCT04970901 |
| AGO Research GmbH | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patients with histologically diagnosed ovarian, fallopian tube, or primary peritoneal cancer 2. Relapsed disease 3. Patients with up to three prior the... | View trial NCT03353831 |
| AGO Research GmbH | Trial sponsor | Mentioned in trial textTrial free-text mention | PDL1 | View trial NCT03353831 |
| AHS Cancer Control Alberta | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patients who were previously on hydroxychloroquine treatment as standard of care therapy or enrolled in IMPACT 2.0 who develop recurrent grade ≥ 2 irAA... | View trial NCT06001125 |
Showing 5 of 3,422 sourcing records.
Trial-cited literature (4,834)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. | The New England journal of medicine | 2026 | 32 |
| Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. | Head & neck | 2026 | 10 |
| Intraperitoneal and intravenous paclitaxel plus S-1 and sintilimab as first-line treatment for gastric cancer with peritoneal metastasis: a single-arm phase 2 trial (DRAGON-09). | EClinicalMedicine | 2026 | 8 |
| Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | 8 |
| Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | 6 |
Showing 5 of 4,834 papers.
Protein variant mentions (45)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D1228N | 1 | 2022 | PMID 36136211 |
| p.D24G | 1 | 2022 | PMID 35857405 |
| p.D265A | 1 | 2022 | PMID 35387780 |
| p.E136A | 1 | 2017 | PMID 28233730 |
| p.E136Q | 1 | 2017 | PMID 28233730 |
Showing 5 of 45 variants.
Literature-extracted relations (2,257)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| PEMETREXED | Chemical | associate |
Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study. | 2026 |
| (nab)-paclitaxel | Chemical | associate |
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. | 2026 |
| Platinum | Chemical | negative_correlate |
Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab. | 2025 |
| GEMCITABINE | Chemical | positive_correlate |
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study. | 2025 |
| Vinorelbine | Chemical | associate |
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study. | 2025 |
Showing 5 of 2,257 relation assertions.
Organizations publishing (1,509)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 371 | 2012 to 2026 |
| Dana-Farber Cancer Institute | Other | 360 | 2000 to 2026 |
| The University of Texas System | Academic | 246 | 2011 to 2026 |
| Harvard Medical School | Academic | 185 | 2000 to 2026 |
| Mass General Brigham | Hospital | 185 | 2004 to 2025 |
Showing 5 of 1,509 organizations.
Where CD274 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
950 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.